Recurrent Verrucous Carcinoma of the Larynx Completed Phase Trials for Gefitinib (DB00317)

Also known as: Laryngeal verrucous carcinoma recurrent / Recurrent Laryngeal Verrucous Carcinoma / Squamous Cell Carcinoma of the Larynx / Laryngeal squamous cell carcinoma / Primary squamous cell carcinoma of larynx (disorder) / Squamous cell carcinoma of larynx (disorder)

IndicationStatusPhase
DBCOND0029506 (Recurrent Verrucous Carcinoma of the Larynx)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00068497Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerTreatment